Early results of an Ebola vaccine efficacy trial show 100% efficacy in individuals, says the World Health Organization.
Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola.
The independent body of international experts— the Data and Safety Monitoring Board—that conducted the review, advised that the trial should continue. Preliminary results from analyses of these interim data are published in the British journal The Lancet.
“This is an extremely promising development,” says Dr Margaret Chan, Director-General of the World Health Organization.
“The credit goes to the Guinean Government, the people living in the communities and our partners in this project. An effective vaccine will be another very important tool for both current and future Ebola outbreaks.”
While the vaccine up to now shows 100% efficacy in individuals, more conclusive evidence is needed on its capacity to protect populations through herd immunity. To that end, the Guinean national regulatory authority and ethics review committee have approved continuation of the trial.